← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Neuraminidase inhibitors
oseltamivir
J05AH02
Forms & Strengths
- Capsule: 30 mg, 45 mg, 75 mg
- Oral Suspension: 6 mg/mL
Adult Dosing
- Treatment of influenza: 75 mg orally twice daily for 5 days
- Prophylaxis of influenza: 75 mg orally once daily for at least 10 days
Pediatric Dosing
- Treatment (infants 2 weeks to <1 year): 3 mg/kg orally twice daily for 5 days
- Treatment (children 1 year and older, weight-based dosing per guidelines)
- Prophylaxis (children 1 year and older, weight-based dosing once daily)
Indications
- Treatment of acute uncomplicated influenza A and B in patients 2 weeks of age and older
- Prophylaxis of influenza in patients 1 year of age and older
Mechanism of Action
- Inhibitor of influenza virus neuraminidase enzymes
- Alters viral particle aggregation and release, inhibiting viral replication
Contraindications
- Known hypersensitivity to oseltamivir or any component of the product
Adverse Reactions
- Nausea
- Vomiting
- Headache
- Neuropsychiatric events (self-injury, delirium, primarily in children)
Drug Interactions
- Live attenuated influenza vaccine (intranasal): Antiviral drugs may inhibit replication of live vaccine; avoid administration within 2 weeks before or 48 hours after vaccine
Curated Content: Needs Vetting Before Put to Clinical Use